CELECOXIB- celecoxib capsule Direct_Rx

CELECOXIB

- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •

- •
- •

Medication Guide for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)? NSAIDs can cause serious side effects, including:

• Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase:

o with increasing doses of NSAIDs o with longer use of NSAIDs Do not take NSAIDs right before or after a heart surgery called a "coronary artery bypass graft (CABG)."

Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack.

• Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines:

o anytime during use o without warning symptoms o that may cause death The risk of getting an ulcer or bleeding increases with:

o past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs o taking medicines called "corticosteroids", "anticoagulants", "SSRIs" or "SNRIs"

- o increasing doses of NSAIDs o older age
- o longer use of NSAIDs o poor health
- o smoking o advanced liver disease
- o drinking alcohol o bleeding problems

NSAIDs should only be used:

o exactly as prescribed o at the lowest dose possible for your treatment o for the shortest time needed

What are NSAIDs?

NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other

types of short-term pain.

Who should not take NSAIDs?

Do not take NSAIDs:

• if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs.

• right before or after heart bypass surgery.

Before taking NSAIDS, tell your healthcare provider about all of your medical conditions, including if you:

- have liver or kidney problems
- have high blood pressure
- have asthma

• are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering taking NSAIDs during pregnancy. You should not take NSAIDs after 29 weeks of pregnancy

• are breastfeeding or plan to breast feed.

Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. NSAIDs and some other medicines can interact with each other and cause serious side effects. Do not start taking any new medicine without talking to your healthcare provider first.

What are the possible side effects of NSAIDs?

NSAIDs can cause serious side effects, including:

See "What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?

- new or worse high blood pressure
- heart failure
- liver problems including liver failure
- kidney problems including kidney failure
- low red blood cells (anemia)
- life-threatening skin reactions
- life-threatening allergic reactions
- Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness.

Get emergency help right away if you get any of the following symptoms:

- shortness of breath or trouble breathing slurred speech
- chest pain swelling of the face or throat
- weakness in one part or side of your body

Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms:

- nausea vomit blood
- more tired or weaker than usual there is blood in your bowel movement or it is black and sticky like tar
- diarrhea unusual weight gain
- itching skin rash or blisters with fever
- your skin or eyes look yellow swelling of the arms, legs, hands and feet

- indigestion or stomach pain
- flu-like symptoms

If you take too much of your NSAID, call your healthcare provider or get medical help right away.

These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Other information about NSAIDs

• Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.

• Some NSAIDs are sold in lower doses without a prescription (over-the counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.

General information about the safe and effective use of NSAIDs

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.

For more information, call at 1-888-943-3210.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured for : Macleods Pharma USA, Inc. Plainsboro, NJ 08536

Manufactured by : Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, INDIA

Revision Date: May 2016

PM02159404

•

Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed. Inform patients, families, or their caregivers of the following information before initiating therapy with celecoxib capsules and periodically during the course of ongoing therapy.

Cardiovascular Thrombotic Events

Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to

report any of these symptoms to their health care provider immediately [see Warnings and Precautions (5.1)].

Gastrointestinal Bleeding, Ulceration, and Perforation

Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their health care provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for and the signs and symptoms of GI bleeding [see Warnings and Precautions (5.2)].

Hepatotoxicity

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, diarrhea jaundice, right upper quadrant tenderness, and "flulike" symptoms). If these occur, instruct patients to stop celecoxib capsules and seek immediate medical therapy [see Warnings and Precautions (5.3), Use in Specific Populations (8.6)].

Heart Failure and Edema

Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [see Warnings and Precautions (5.5)].

Anaphylactic Reactions

Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [see Contraindications (4) and Warnings and Precautions (5.7)].

Serious Skin Reactions

Advise patients to stop celecoxib capsules immediately if they develop any type of rash and to contact their healthcare provider as soon as possible [see Warnings and Precautions (5.9)].

Female Fertility

Advise females of reproductive potential who desire pregnancy that NSAIDs, including celecoxib capsules, may be associated with a reversible delay in ovulation [see Use in Specific Populations (8.3)].

Fetal Toxicity

Inform pregnant women to avoid use of celecoxib capsules and other NSAIDs starting at 30 weeks of gestation because of the risk of the premature closing of the fetal ductus arteriosus [see Warnings and Precautions (5.10) and Use in Specific Populations (8.1)].

Avoid Concomitant Use of NSAIDs

Inform patients that the concomitant use of celecoxib capsules with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [see Warnings and Precautions (5.2) and Drug Interactions (7)]. Alert patients that NSAIDs may be present in "over the counter" medications for treatment of colds, fever, or insomnia.

Use of NSAIDS and Low-Dose Aspirin

Inform patients not to use low-dose aspirin concomitantly with celecoxib capsules until they talk to their healthcare provider [see Drug Interactions (7)].

Manufactured for : Macleods Pharma USA, Inc. Plainsboro, NJ 08536

Manufactured by : Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, INDIA

Revision Date: October 2018





CELECOXIB celecoxib capsule **Product Information** HUMAN PRESCRIPTION **Item Code** NDC:61919-682(NDC:33342-**Product Type** DRUG (Source) 156) **Route of Administration** ORAL **Active Ingredient/Active Moiety Ingredient Name Basis of Strength** Strength CELECOXIB (UNII: JCX84Q7J1L) (CELECOXIB - UNII: JCX84Q7J1L) CELECOXIB 100 mg **Inactive Ingredients** Strength **Ingredient Name** POVIDONE (UNII: FZ989GH94E) SODIUM LAURYL SULFATE (UNII: 368GB5141)) HYDROXYPROPYL CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) GELATIN (UNII: 2G86QN327L) FD&C BLUE NO. 2 (UNII: L06K8R7DQK) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) **Product Characteristics** Color white Score no score Shape CAPSULE Size 14mm Flavor **Imprint Code** C5;100mg Contains

# Item Cod	e Pa	ckage Description	Μ	larketing S Date	Start Ma	arketing End Date	
1 NDC:61919-68	82- 30 in 1 BOTTL Product	E; Type 0: Not a Combinatio	n 11/1	.9/2021			
2 NDC:61919-68	82- 60 in 1 BOTTL Product	E; Type 0: Not a Combinatio	n 11/1	9/2021			
Marketin	g Informat	ion					
Marketing Category		tion Number or Monograph Citation		Marketing Start Date		Marketing End Date	
ANDA	ANDA20459	0	1	1/19/2021			
	_						
CELECOXI	-						
elecoxib caps	sule						
Product Inf	ormation						
Product Type		HUMAN PRESCRIPTION DRUG	ltem Code (Source)		NDC:61919-360(NDC:60505- 3849)		
Route of Adm	inistration	ORAL	•••••				
Active Ingre	edient/Active	Moiety					
	Ingred	lient Name		Basis	of Strengt	h Strengtl	
CELECOXIB (UN	III: JCX84Q7J1L) (CI	ELECOXIB - UNII:JCX84Q7J1L)		CELECOX	В	200 mg	
Inactive Ing	iredients						
	leaches						
		Ingredient Name				Strength	
-		Ingredient Name				Strength	
	(UNII: 92RU3N3Y1C))				Strength	
DIMETHICONE	YELLOW (UNII: EX)) 43802MRT)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC	YELLOW (UNII: EX	0) 43802MRT) M416302)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T	0) 43802MRT) M416302)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T 2G86QN327L)	0) 43802MRT) M416302)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2 SHELLAC (UNII:	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T 2G86QN327L) 46N107B71O)	0) 43802MRT) M416302)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2 SHELLAC (UNII: ALCOHOL (UNII:	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T: 2G86QN327L) 46N107B71O) 3K9958V90M)	0) 43802MRT) M416302) S3)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2 SHELLAC (UNII: ALCOHOL (UNII: MAGNESIUM ST	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T 2G86QN327L) 46N107B71O) 3K9958V90M) TEARATE (UNII: 70	0) 43802MRT) M416302) S3) 097M6I30)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2 SHELLAC (UNII: ALCOHOL (UNII: MAGNESIUM ST SODIUM LAURY	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T: 2G86QN327L) 46N107B71O) 3K9958V90M) TEARATE (UNII: 70 TL SULFATE (UNII:	0) 43802MRT) M416302) 53) 097M6I30) 368GB5141J)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2 SHELLAC (UNII: ALCOHOL (UNII: MAGNESIUM ST SODIUM LAURY TITANIUM DIOX	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T 2G86QN327L) 46N107B71O) 3K9958V90M) FEARATE (UNII: 70 L SULFATE (UNII: KIDE (UNII: 15FIX9V	0) 43802MRT) M416302) 53) 097M6I30) 368GB5141J)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2 SHELLAC (UNII: ALCOHOL (UNII: MAGNESIUM ST SODIUM LAURY TITANIUM DIOX POVIDONE (UNII	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T 2G86QN327L) 46N107B71O) 3K9958V90M) TEARATE (UNII: 70 7L SULFATE (UNII: KIDE (UNII: 15FIX9V I: FZ 989GH94E)	0) 43802MRT) M416302) 53) 097M6I30) 368GB5141J)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2 SHELLAC (UNII: ALCOHOL (UNII: MAGNESIUM ST SODIUM LAURY TITANIUM DIOX POVIDONE (UNII:	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T: 2G86QN327L) 46N107B710) 3K9958V90M) TEARATE (UNII: 70 7L SULFATE (UNII: KIDE (UNII: 15FIX9V I: FZ 989GH94E) 5138Q19F1X)	0) 43802MRT) M416302) 53) 097M6I30) 368GB5141J) /2JP)				Strength	
DIMETHICONE FERRIC OXIDE ISOPROPYL ALC BUTYL ALCOHO GELATIN (UNII: 2 SHELLAC (UNII: ALCOHOL (UNII: MAGNESIUM ST SODIUM LAURY TITANIUM DIOX POVIDONE (UNII: AMMONIA (UNII: PROPYLENE GL	YELLOW (UNII: EX COHOL (UNII: ND2 DL (UNII: 8PJ61P6T 2G86QN327L) 46N107B71O) 3K9958V90M) TEARATE (UNII: 70 7L SULFATE (UNII: KIDE (UNII: 15FIX9V I: FZ 989GH94E)	D) 43802MRT) M416302) 53) 097M6I30) 368GB5141J) /2JP) Q167V3)				Strength	

Product Characteristics

Color		white	Score	Score		
Shape		CAPSULE	Size	Size		
Flavor			Imprint Code		APO;C200	
Co	ontains					
Pa	ackaging					
#	ltem Code	Package De	escription	Marketing Start Date	Marketing End Date	
1	NDC:61919-360- 10	10 in 1 BOTTLE; Type 0: Product	Not a Combination 0	3/02/2016		
		15 in 1 BOTTLE; Type 0: Product	Not a Combination 0	3/02/2016		
N	larketing l	nformation				
•		Application Num	Application Number or Monograph Citation		Marketing End	
	Marketing Category		ation	Date	Date	

Labeler - Direct_Rx (079254320)

Registrant - Direct_Rx (079254320)

Establishment								
Name	Address	ID/FEI	Business Operations					
Direct_Rx		079254320	repack(61919-360, 61919-682)					

Revised: 4/2023

Direct_Rx